180 Life Sciences Corp (ATNF)
$1.765
Live
Insights on 180 Life Sciences Corp
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 49.7% return, outperforming this stock by 141.0%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 240.7% return, outperforming this stock by 340.6%
Performance
- $1.68$1.82$1.77
5.08%
Downside
Day's Volatility :7.57%
Upside
2.62%
- $1.33$27.93$1.77
24.86%
Downside
52 Weeks Volatility :95.24%
Upside
93.66%
Returns
| Period | 180 Life Sciences Corp | Russel 2000 | Index (Russel 2000) |
|---|---|---|---|
3 Months | -55.96% | 0.0% | 0.0% |
6 Months | -78.62% | 0.0% | 0.0% |
1 Year | -91.29% | 1.3% | 1.3% |
3 Years | -99.95% | -22.1% | -22.1% |
Highlights
Market Capitalization | 1.6M |
Book Value | - $0.24 |
Earnings Per Share (EPS) | -52.59 |
Wall Street Target Price | 80.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -67.63% |
Return On Equity TTM | -355.47% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -13.4M |
Diluted Eps TTM | -52.59 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 4432.58%
Technicals Summary
Sell
Neutral
Buy
180 Life Sciences Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 180 Life Sciences Corp | -13.75% | -78.62% | -91.29% | -99.95% | -82.4% |
 Moderna, Inc. | -1.39% | 41.81% | -19.31% | -38.71% | 322.88% |
 Regeneron Pharmaceuticals, Inc. | -5.68% | 13.74% | 14.81% | 80.88% | 159.02% |
 Novo Nordisk A/s | -2.24% | 29.49% | 49.67% | 240.51% | 421.0% |
 Vertex Pharmaceuticals Incorporated | -3.67% | 10.39% | 20.74% | 84.71% | 129.52% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
180 Life Sciences Corp | 3.47 | NA | NA | 0.0 | -3.55 | -0.68 | NA | -0.24 |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.77 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.13 | 26.13 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 48.36 | 48.36 | 2.4 | 3.34 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 29.17 | 29.17 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
180 Life Sciences Corp | Buy | $1.6M | -82.4% | 3.47 | 0.0% |
Moderna, Inc. | Buy | $41.3B | 322.88% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.6B | 159.02% | 26.13 | 30.14% |
Novo Nordisk A/s | Buy | $573.9B | 421.0% | 48.36 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $104.7B | 129.52% | 29.17 | 36.68% |
Institutional Holdings
Charles Schwab Investment Management Inc
3.10%Virtu Financial LLC
0.68%Vanguard Group Inc
0.42%Renaissance Technologies Corp
0.38%HRT FINANCIAL LLC
0.33%Geode Capital Management, LLC
0.27%
Company Information
180 life sciences corp., a clinical-stage biotechnology company, engages in the development of drug candidates in the areas of inflammatory diseases, fibrosis, and pain. its product development platforms in phase iib/iii clinical trials include fibrosis and anti-tnf platform, which focuses on fibrosis and anti-tumor necrosis factors; synthetic cannabidiol (cbd) analogs platform, which are man-made derivatives of cbd; and a7nachr platform, which focuses on alpha 7 nicotinic acetylcholine receptor. the company is headquartered in menlo park, california.
Organization | 180 Life Sciences Corp |
Employees | 4 |
CEO | Dr. Lawrence Steinman BA, M.D., Ph.D. |
Industry | Finance |
